Beardsworth Consulting Group, Inc.
Wikipedia 🌐 NONE
Founder - Donna E. Beardsworth (born 1956)
Employees and consultants incude :
EVIDENCE TIMELINE
2009 (Nov 24) - AppliedClinicalTrialsOnline.com : "Beardsworth Selects OmniComm Systems TrialMaster Solution for the EDC of a Phase II Vaccine Study"
Published on: November 24, 2009 / Fort Lauderdale, FL
2009-11-24-appliedclinicaltrialsonline-com-beardsworth-selects-omnicomm-systems-trialmaster-solution-edc-phase-ii-vaccine-study.pdf
2009-11-24-appliedclinicaltrialsonline-com-beardsworth-selects-omnicomm-systems-trialmaster-solution-edc-phase-ii-vaccine-study-img-1.jpg
OmniComm Systems, Inc. announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm’s TrialMaster EDC solution for conducting a Phase II vaccine study. The 3-year, 10-site study is planning to enroll 340 subjects.
"After a careful selection process, we chose OmniComm Systems to be our preferred EDC provider,” said Michael J. O’Brien, Beardsworth President and CEO.
OmniComm and Beardsworth plan electronic imports of data to TrialMaster EDC utilizing OmniComm’s native, template matching, subsystem. Electronic exports from TrialMaster EDC to Beardsworth’s BNet portal will be achieved utilizing OmniComm’s new RESTful Web Services, Application Programming Interface (API). This API technology, developed using a RESTful Web Services architecture, leverages CDISC standards and allows for easy integration with external data sources like BNet.
2010 (June 25) - BioSpace.com : "Alison Martin, MD and Robert W. Malone, MD Join Beardsworth Consulting Group, Inc. (BCGI)"
Saved as PDF : [HW00AU][GDrive]
Regarding : Beardsworth Consulting Group, Inc. / Donna E. Beardsworth (born 1956) / Dr. Robert Wallace Malone (born 1959)
Alison Martin in 2001 NCI book ... https://www.cancer.gov/about-nci/budget/fact-book/archive/2001-fact-book.pdf
Also in newspapers : https://www.newspapers.com/image/364574948/?terms=beardsworth&match=1
FLEMINGTON, N.J., June 24 /PRNewswire/ -- [Beardsworth Consulting Group, Inc.] announces the appointments of Alison Martin, M.D. as the company's Scientific Advisor, Oncology and Robert W. Malone, M.D. as the company's Medical Director, Vaccines.
Dr. Alison Martin is one of oncology's respected research leaders with over 20 years of clinical research experience. She joins Beardsworth from the National Cancer Institute (NCI) where she was most recently Head of Genitourinary Cancers and Melanoma Therapeutics in the Clinical Investigations Branch of the Cancer Therapy Evaluation Program (CTEP). Dr. Martin was scientific co-chair along with Dr. Meenhard Herlyn of the 2007 NCI-Community-Oriented Strategic Action Plan for Melanoma Research. She has served as liaison to three of NCI's cooperative groups and been a senior investigator in the Investigational Drug Branch of CTEP. In addition to experience at NCI, Dr. Martin was a team leader in the Office of Oncology Drug Products at the U.S. Food and Drug Administration and has experience working with the biotechnology and pharmaceutical industries.
[Dr. Robert Wallace Malone (born 1959)] has extensive experience in viral and recombinant vaccines, biodefense, gene delivery and transfer, immunology, tissue and cell culture, and DNA vaccination in both the commercial and government market sectors. An internationally recognized scientist, Dr. Malone is known as one of the original inventors of "DNA Vaccination" holding numerous fundamental domestic & foreign patents in the fields of gene delivery, delivery formulations, and vaccines. His background includes over 25 years of experience in academia and industry, including both founding and working with a wide range of pharmaceutical and biotech companies. He has experience in federal contracting, working with NGO's in health related research and development as well as relationships with CDC, DOD and HHS. Dr. Malone is involved with 15 issued patents, has numerous publications and two book chapters in this field, and serves as editor-in-chief of the Journal of Immune Based Therapies and Vaccines.
"We are honored and excited to have Alison and Robert join the Beardsworth team," said Michael J. O'Brien, President and CEO, Beardsworth. He added, "the increasing demands of Oncology and Vaccine research, individually and together, place Beardsworth in an attractive position given our many years of experience in these two areas. Alison and Robert will provide valuable expertise and vision to the expanding clinical research needs of our growing client base."
As members of Beardsworth's team, Drs. Martin and Malone join other noted industry experts whose collective strategic scope and in-depth knowledge support Beardsworth's mission of delivering superior quality clinical services, on time and on budget.
Headquartered in Flemington, New Jersey, Beardsworth is a privately held contract research organization delivering research and business solutions for clinical research programs since 1986. Focused on complicated trials in complex therapeutic areas, Beardsworth's clinical team expertise, advanced technology platform, and "Investigator Express" process provide clients with a patient-centric approach to study management, patient recruitment and cost-effective solutions. Beardsworth is a WBENC-certified, woman-owned business and registrant with CCR.
- SOURCE Beardsworth Consulting Group, Inc.
2010 (Aug 10) - BioSpace.com :
https://www.biospace.com/article/releases/bioclinica-inc-partners-with-axio-research-corporation-aquired-by-solutia-inc-and-beardsworth-consulting-group-inc-bcgi-/
BioClinica, Inc. Partners with Axio Research Corporation (Aquired by Solutia, Inc and Beardsworth Consulting Group, Inc. (BCGI®)
Published: Aug 10, 2010
NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced it has created strategic partnerships with two privately held clinical research organizations (CROs), Axio Research Corporation and Beardsworth Consulting Group, Inc. Both alliances strengthen the BioClinica Certified Partner Program and provide customers with additional support in complex therapeutic areas of study and data monitoring and management.
FLEMINGTON, N.J., March 23, 2011 /PRNewswire/ -- Donna E. Beardsworth, age 54, the Founder, President & CEO of the Contract Research Organization, Beardsworth Consulting Group, Inc., passed away unexpectedly early Sunday morning.
"We are shocked and greatly saddened by the passing of Donna. She was a dear friend who cared deeply about people and humanity. Donna was a visionary leader, a devoted clinician and a mentor to many within the Clinical Research Industry. The people with whom she worked over the years will deeply mourn her loss and miss her spirit. We extend our sympathies to her family and all of her friends," said Vincent F. DiBianca, a principal in the company.
The Board has appointed Michael O'Brien as the President & CEO. Mr. O'Brien, who has been with the company for nine years, previously served for the past four and a half years as President & CEO, until December, 2010.
"Donna's vision for our company was to focus on complicated clinical trials in Oncology and other difficult therapeutic areas. Her goal was to make an impactful difference in healthcare. She was a true pioneer in the CRO industry, and we have all been inspired by her dedication and limitless spirit," said Mr. O'Brien. "Donna was very proud to be ushering in the 25th anniversary of Beardsworth this year, and the company is fully committed to continuing her legacy."
In recognition of her corporate stewardship and vision, Donna was honored with the Entrepreneur of the Year Award by the Hunterdon County Chamber of Commerce. Donna Beardsworth's high standards and steadfast commitment to quality and integrity are reflected in the company's recent successes and growth.
- SOURCE Beardsworth Consulting Group, Inc.
2011 (May 05) - BioSpace.com :
2011-05-05-biospace-com-beardsworth-consulting-group-inc-bcgi-continues-to-strengthen-oncology-operations.pdf
https://drive.google.com/file/d/1XIvcsyKYt3a_DZvZV30DT9tvrnpHn7Co/view?usp=share_link
Beardsworth Consulting Group, Inc. (BCGI®) Continues to Strengthen Oncology Operations
Published: May 05, 2011
FLEMINGTON, N.J., May 4, 2011 /PRNewswire/ -- Beardsworth announces the promotion of Evette Riegel, RN, to Senior Director, Clinical Operations and Project Management and the addition of Saishree Ramalingam, MS, MPhil as Senior Project Manager.
(Photo: http://photos.prnewswire.com/prnh/20110504/NY95605 )
In her new role, Ms. Riegel will lead Beardsworth's expanded focus in oncology clinical operations and execution of all clinical programs.
"Evette's expertise and insight provide an added dimension that strengthens our client services and capabilities across our global OncologyOne(SM) and therapeutic vaccine initiatives. Her global trial experience and extensive therapeutic knowledge combined with her personal insight as a critical care nurse, give her a unique perspective from which to lead our patient-centric, project management teams," said Michael O'Brien, President & CEO.
Ms. Riegel joined Beardsworth in 2006 as a Senior Project Manager and became Director, Clinical Operations in 2008 with a leading role in the integration of Beardsworth's global services and oncology operations. Previously, Ms. Riegel worked at Quintiles as a global project manager as well as Discovery Laboratories, ViroPharma, and Wyeth.
Saishree Ramalingam, MS, MPhil joins Beardsworth as a Senior Project Manager responsible for leading the company's oncology trials. An experienced research clinician, Ms. Ramalingam has over 13 years experience across multiple therapeutic areas and global projects with a special focus in oncology and vaccines.
Prior to Beardsworth, Ms. Ramalingam held project manager positions at Celgene, Pfizer, GSK/Reliant, Merck, as well as PharmaNet, Applied Clinical Intelligence, and PRA International. She received her master of science at the University of Akron and a master of philosophy from Avinashilingam Deemed University, Coimbatore, India.
"We are thrilled to have Saishree on the Beardsworth team," said Evette Riegel. "The depth and scope of her expertise, global project experience, and strong cross-functional leadership capabilities are immediate assets to our clients, our partners, and our project teams."
Headquartered in Flemington, New Jersey, Beardsworth is a full-service CRO specializing in business solutions for complex clinical trials focused on oncology and therapeutic vaccine. Our multi-disciplined staff averages 20+ years experience supporting research studies from trial design through clinical project management to FDA approval. Beardsworth is the founding partner of OncologyOne(SM) an alliance of best-in-class regional CROs providing full-service strategies for global oncology trials. Celebrating its 25th year, Beardsworth is a CCR registrant and Certified Small Business.
2013 (April 30) -
2013-04-30-biospace-com-tfs-b-acquires-us-oncology-and-vaccine-specialist-beardsworth-consulting-group-inc.pdf
https://drive.google.com/file/d/142xjjwH64DvLOlVFkZUPSHoa2f5UR5rw/view?usp=share_link
2013-04-30-biospace-com-tfs-b-acquires-us-oncology-and-vaccine-specialist-beardsworth-consulting-group-inc-img-1
https://drive.google.com/file/d/17ka5f43mNFXz7TKSRmE82JU_FMAANsib/view?usp=share_link
TFS Acquires US Oncology and Vaccine Specialist Beardsworth Consulting Group, Inc. (BCGI®)
Published: Apr 30, 2013
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LUND, Sweden, April 30, 2013 /PRNewswire/ -- On April 26th, 2013, TFS International (TFS) has completed the acquisition of the New Jersey based Oncology and Vaccine specialist Contract Research Organization (CRO), Beardsworth Consulting Group, Inc. (BCG).
In a move to expand its oncology and vaccine research services, TFS has announced the completion of acquiring BCG, an independent clinical CRO with headquarters in Flemington, New Jersey, and with clinical research professionals located throughout North America. BCG was established by Ms. Donna Beardsworth in 1986 and, through her commitment to clinical research and entrepreneurship, BCG became a recognized and trusted industry leader in the execution of complex clinical trials within oncology, vaccines, and other important therapeutic areas.
The acquisition of BCG follows the TFS global strategy to grow its North American operations to 600 professionals with comparable capabilities and expertise to its existing European business. The BCG acquisition will complement TFS' competences in oncology and vaccines, among several others therapeutics areas, as well as provide scalable operational resources throughout North America. BCG's operations include comprehensive clinical research services together with project management and monitoring across all study phases, data management, biostatistics, regulatory consulting, and medical writing.
"The BCG deal is really a welcomed component in the strategic vision of TFS. It adds competencies in active and growing therapeutic areas, increases our operational capabilities in North America and expands substantially our customer portfolio of smaller and midsized life science companies in one of the most important global research markets. It aligns very well with where we want to be as a company," said Mr. Daniel Spasic, Chief Executive Officer at TFS.
TFS has recently completed several acquisitions and the BCG deal follows two other transactions in the last five months, including the acquisition of Dimensione Ricerca in Italy and the technology provider for Electronic Data Capture (EDC) services, Semcon in Sweden.
"We are very pleased to have found a global partner through the TFS Group. TFS and BCG share a common culture of quality and professional service of the highest caliber. As a combined operation, we now have significant resources deployed across multiple continents. It is rewarding to know that our global capabilities will now provide considerable value to our clients, and the patients that we ultimately serve. I have the highest confidence that the combined TFS/BCG team will create true synergies and material benefit to the biopharmaceutical industry, under the TFS name," said Mr. Doug Beardsworth, Executive Chairman at BCG.
TFS and BCG have had a history of collaboration on several global clinical programs in oncology and other therapeutic areas. Operational processes and quality systems have been well established which will facilitate an efficient integration between the two groups as well as ensuring business continuity and focus on the ongoing clinical projects and customers.
"Mr. Hani Zaki will be taking the helm for the TFS US organization as the Executive VP and President Americas. He is a seasoned and trusted pharmaceutical and CRO executive who has spent many years working for public and private CROs, and is a well-respected professional within the life science community," said Mr. Spasic.
The terms and conditions of the acquisition have not been disclosed.
For further information please contact:
Ms. Gordana Claveres, MSc.
Marketing and Communications Associate
TFS International
E-mail: gordana.claveres@tfscro.com
Information about TFS
TFS International is one of the largest privately owned clinical Contract Research Organizations (CROs) founded in 1996 in Sweden, currently operating in 20 countries with offices throughout Europe, the USA and Japan. TFS supports multiple therapeutic areas and their services are provided worldwide through four business verticals: TFS ExploreTM, TFS DevelopTM, TFS PeopleTM and TFS AcademyTM. Detailed information about TFS, its business offerings, global locations and recent press releases can be obtained through www.tfscro.com
SOURCE TFS International